

Ajanta House, Charkop, Kandivli West, Mumbai 400 067 India

T +91 22 6606 1000
F +91 22 6606 1200
E info@ajantapharma.com
W www.ajantapharma.com

3rd January, 2017

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001

National Stock Exchange of India, Exchange Plaza, 5th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: BSE - AJANTPHARM 532331/ NSE - AJANTPHARM EQ

Re: Compliance with Reg. 27(2) of the Listing Regulations - Report on Corporate Governance

Dear Sir/Madam,

Pursuant to Regulation 27(2) of the Listing Regulation, enclosed please find quarterly Compliance Report on Corporate Governance (CG) for the quarter ended on 31st December, 2016.

Thanking You,

Yours faithfully,

GAURANG SHAH Sr. G.M. - Legal & Company Secretary

Encl.: a/a

Name of Listed Entity
 Quarter ending

: Ajanta Pharma Limited : 31st December, 2016

I. Composition of Board of Directors					· · · · · · · · · · · · · · · · · · ·	
Title Name of the Director PAN\$ (Mr. / Ms)	Category (Chairperson /Executive/ Non- Executive/ independent / Nominee) ⁶	Date of Appointment in the current term /cessation	Tenu re	No of Directorship in listed entities including this listed entity (Refer Regulation 25(1) of Listing Regulations)	memberships in Audit/ Stakeholder Committee(s) including this listed	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)
	"SAME A	AS PREVIOUS QU	JARTER'			
II. Composition of Committees						
III Marchina of Board of Biratan	"SAME A	AS PREVIOUS QU	JARTER"			
III. Meeting of Board of Directors						
Date(s) of Meeting (if any) in the previous qu	, , ,	Date(s) of Meeting (if any) in the relevant quarter		Maximum gap between any two consecutive (in number of days)		
26 th July, 2016	26 th October,	26 th October, 2016		91 (excluding meeting days)		
IV. Meeting of Committees						
Date(s) of meeting of the committee relevant quarter	in the Whether req Quorum met (details) 1	the com	of meeting of mittee in the quarter	Maximum gap be consecutive meetings	etween any two in number of days*
Audit Committee: 26 th October, 2016		Yes, all the Committee 26 th July members were present			91 (excluding meeting	; days)
Stakeholders' Relationship Committee: 26 th October, 2016	Yes, all the members were		26 th July	, 2016	91 (excluding meeting	; days)



V. Related Party Transactions	
Subject	Compliance status (Yes/No/NA)refer note below
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	NA
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by	Yes
Audit Committee	
VI. Affirmations	
	I

- 1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2. The composition of the following committees is in terms of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015
 - a. Audit Committee
 - b. Nomination & Remuneration committee
 - c. Stakeholders relationship committee
- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.

5. This report will be placed before Board of Directors at the ensuing Board meeting.

Name & Designation: Gaurang C. Shah

Company Secretary / Compliance Officer / Managing Director / CEO: Company Secretary & Compliance Officer

For AJANTA PHARMA LIMITED

GAURANG SHAH

Sr. G.M. - Legal & Company Secretary